Amiodarone-induced thyrotoxicosis is a life-threatening problem that is very effectively managed by total thyroidectomy, although often many of these patients are considered "too unfit" for anaesthesia. The aim of this study was to review the safety of anaesthesia for total thyroidectomy in the acute management of amiodarone-induced thyrotoxicosis.
Amiodarone is a Class III anti-arrhythmic drug which has been used in Europe since 1967 to treat angina and refractory arrhythmias of supraventricular, junctional and ventricular origin and used in the United States since 1986 for the management of ventricular and supraventricular arrhythmias. Amiodarone-induced thyrotoxicosis (AIT) was initially reported by Jonckheer et al in 1973 when two cases were described 1 .
The most important component of the management of AIT is withdrawal of amiodarone. Unfortunately there is a significant sub-group of patients who are refractory to other anti-arrhythmic agents, in whom it is impossible to withdraw amiodarone. Whilst this represents less than 5% of patients in our institution, they are a particularly difficult management group. More importantly, withdrawal of amiodarone in patients in whom this is possible may not result in any significant ameloriation of thyrotoxicosis for many months, exposing the patient to grave risks of continuing cardiac instability. It is therefore sometimes imperative that AIT is rapidly reversed and the patient rendered euthyroid. The logical way of achieving this result is to remove the source-organ, namely to perform a total thyroidectomy, thus immediately rendering the patient hypothyroid, and able to tolerate amiodarone without the risk of complications.
The prevailing view is that anaesthesia in this group of patients with uncontrolled thyrotoxicosis is a highrisk procedure associated with an unacceptable rate of anaesthetic complications. Indeed, patients are often refused a life-saving procedure on the basis that they are "too unfit" for anaesthesia. It has been our experience, however, that total thyroidectomy for AIT is a relatively straightforward procedure. Thyrotoxic storm does not occur, anaesthesia is relatively safe, and surgical complications are minimal as the gland is generally small and fibrotic, making surgical dissection and removal of the gland safe.
Traditional anaesthetic teaching is to avoid general anaesthesia in patients with uncontrolled hyper-thyroidism or thyrotoxicosis, because of the risk of precipitating a thyroid storm. The latter is a life-threatening acute hyperthyroid state that is associated with a mortality of 10 to 50% 2 . The other area of concern for anaesthetists is provision of anaesthesia when cardiac failure and/or rapid arrhythmias are uncontrolled. While prospective controlled clinical trials are not available, application of sensible "first principle" guidelines suggest delaying elective surgery until cardiac status is optimized 3 . However the patient with AIT usually presents a management dilemma.
The aim of this case study was to examine the role of anaesthesia and total thyroidectomy in the acute management of AIT.
METHODS
Data was obtained from hospital records and a prospective endocrine surgery database maintained at the Royal North Shore Hospital, a tertiary referral hospital. From the database, 2096 records were found for patients who had undergone total thyroidectomy between 1970 and 1999. Of these patients, 60 had undergone surgery for a diffuse toxic goitre and, of this subgroup, 12 were found to have had AIT requiring urgent surgery. All of these patients underwent surgery during the six-year period from 1993 and 1999. All patients underwent total thyroidectomy and received thyroxine replacement postoperatively.
RESULTS
The clinical findings of the 12 patients who required surgery for refractory AIT are detailed in Table 1 . All were still receiving amiodarone at the time of diagnosis of AIT. Four patients were receiving ß-blockers and a further two were receiving calcium antagonists, despite known interactions of ß-blockers and calcium antagonists with amiodarone that can lead to sinus bradycardia and sinus arrest 4 . All patients had failed to respond to medical management of their AIT.
Of the 12 patients who presented for surgery, 11 received uneventful general anaesthesia, and one local anaesthesia with sedation. Details of anaesthetic technique are given in Table 2 .
Where general anaesthesia was employed, typically no premedication or a small dose of oral temazepam (10 or 20 mg with or without oral ranitidine 150 mg) was given. In one case oral lorazepam was used due to extreme patient anxiety. Induction was performed with fentanyl 1.5 to 3 µg/kg and propofol 0.5 to 1 mg/kg or thiopentone 2 to 4 mg/kg, followed by nondepolarizing muscle relaxant (vecuronium or rocuronium). Anaesthesia was maintained with oxygen/nitrous oxide and isoflurane or sevoflurane.
Haemodynamics were typically stable. Although metaraminol was given to 50% of cases to treat hypotension (systolic blood pressure (SBP) <90 mmHg), this was usually only on one occasion immediately postoperatively. Routine monitoring included electrocardiogaphy, noninvasive blood pressure measurement, pulse oximetry, end-tidal capnography and agent monitoring. For patients 2,3,5,8 and 9, direct intra-arterial pressure monitoring was employed, and for patient 3, pulmonary arterial pressure monitoring was added. Where local anaesthesia was employed, midazolam in 0.5 to 1 mg increments was given and fentanyl in 25 µg increments.
No patient died as a consequence of surgical treatment for AIT despite the presence of uncontrolled thyrotoxicosis and, in many instances, cardiac instability or cardiac failure. There was no morbidity attributable to anaesthesia. Surgical complications occurred in three patients. Two patients required reexploration for postoperative haemorrhage presenting in the early recovery period, with no prolongation of hospital stay. One patient developed a neuropraxia of the recurrent laryngeal nerve, which recovered after three months. All patients were able to continue amiodarone therapy for their cardiac arrhythmia after surgery.
DISCUSSION
Amiodarone is a Class III anti-arrhythmic drug which is now know to be associated with the development of AIT. It is a fat-soluble iodinated bendrofuran derivative with a half-life between 28 and 100 days 5 . Both the drug and its major metabolite, desethylamiodarone, have been detected in plasma nine months after cessation of the drug 6 . The documented side-effects of amiodarone are numerous, with complications affecting up to 52% of patients. These complications include both hyperthyroidism and hypothyroidism.
The incidence of thyroid dysfunction during the administration of amiodarone is very high. A review of 17 studies including 1630 patients reported an incidence of AIT of 3% 7 . The prevalence of thyroid dysfunction associated with amiodarone seems to be related to the dietary content of iodine, such that thyrotoxicosis is more commonly seen in areas of low iodine intake whereas hypothyroidism is more commonly seen in iodine-replete areas 8 . The time of onset of AIT varied between two weeks after initiation of amiodarone therapy up to two months after cessation of the drug. The rapid onset of AIT and the unpredictable nature of onset after administration of amiodarone imply that the monitoring of TSH levels to allow early detection of AIT is of no clinical value 9 .
AIT has been subdivided into two types: Type I AIT is associated with pre-existing thyroid disease, either multinodular goitre or latent Graves' Disease, whereas Type II AIT occurs in an apparently normal thyroid gland and is probably due to iodine, amiodarone or desethylamiodarone-induced thyroid damage. The mechanism of action by which AIT is induced is not fully understood, but Type I AIT is believed to be due in part to the very high levels of iodine within amiodarone (a dose of 200 mg amiodarone generates 6 mg iodine). It is well known that excess iodine itself can induce thyrotoxicosis. Type II AIT is probably due to a direct injury of the thyroid follicular cells 10 . The differing aetiology of the two types of AIT implies that different treatments may be appropriate for the two different mechanisms of action.
The clinical findings of AIT are, as expected, similar to those when hyperthyroidism is due to iodine overload. However, AIT often has a very rapid onset and may occur any time after commencing amiodarone therapy, thus rendering monitoring of thyroid function tests unhelpful. The most frequently described symptoms include weight loss, aesthenia, restlessness, hyperkinesia, pyrexia and recurrence of the arrhythmia for which the patient was initially prescribed amiodarone. The results of thyroid function tests are unreliable, but will usually show high-normal or raised free T4 with low or undetectable thyroid stimulating hormone or raised free T3 and rT3 11 .
Numerous treatments for AIT have been proposed and, indeed, if amiodarone (or any other iodine source) is withdrawn from the patient, the AIT will regress eventually. Unfortunately, this may take many months and the patient is often unable to tolerate the effects of severe thyrotoxicosis for a long period. Similarly, the cardiac arrhythmia for which amiodarone was initially prescribed may be refractory to other anti-arrhthymic agents and so it may be impossible to withdraw amiodarone completely. In these patients it is therefore often imperative that AIT be rapidly reversed and the patient rendered euthyroid, something that can only be achieved by total removal of the thyroid gland. Some of the treatments described for AIT include the administration of methimazole to block the synthesis of thyroid hormones 12 , potassium perchlorate (KClO 4 ) to deplete intrathyroidal iodine stores 8 , glucocorticoids to stabilize the membranes of follicular cells 13, 14 , plasmapheresis 15 , lithium 16 and radioiodine. The use of the latter is often ineffective, as the high serum levels of iodine suppress the uptake of the administered radio-active iodine and render its action unreliable and inefficient 17 .
A further option available in the management of these patients is surgery. Total thyroidectomy, which immediately removes the source of all thyroxine production, is indicated if there is insufficient time to allow medical treatment of thyrotoxicosis and rapid return to a euthyroid state is desirable due to its severity. Thyroidectomy is also indicated if amiodarone cannot be withdrawn from the patient because of the underlying cardiac arrhythmia. Occasionally AIT has been noted to be refractory to medical treatment 18 .
The clinical nature of AIT is characterized by a rapid onset and it may often be severe. Late complications of medical treatment must also be kept in mind when treating AIT medically. Problems include treatment failure after initial control of the thyrotoxicosis 19 , and that the patient may be rendered hypothyroid or develop a goitre 20 . A case of anaplastic carcinoma of the thyroid has also been reported following radio-iodine treatment for AIT 21 . Surgery, on the other hand, has generally produced good outcomes and results in a rapid return to normal of serum levels of T3 and of T4 6 . The apparent concern in recommending thyroidectomy for AIT relates largely to the perceived risks of anaesthesia in the uncontrolled thyrotoxic patient.
With respect to those risks, no episodes of thyroid storm have been described. If it is considered the patient is unlikely to tolerate general anaesthesia, the procedure can be readily performed under local anaesthesia. However, our experience has been that cardiovascular stability is better under general anaesthesia than local anaesthesia with sedation, for what is a distressing and uncomfortable surgical experience. Only one previous series in the surgical literature has described the anaesthetic technique for thyroidectomy for AIT 22 . In this Belgian report, 15 patients received total intravenous anaesthesia (TIVA) using sufentanil and propofol and anaes-thesia was apparently uncomplicated. The authors made an unsupported comment that they preferred to avoid volatile agents because of their potential "to precipitate arrhythmias in hyperthyroid patients".
The surgical management of AIT is still not well defined. To date only 46 patients have been reported undergoing thyroidectomy for AIT 6, 7, 18, 20, 22, 23 and it appears to be regarded as the therapy of last choice when all else has failed. Hitherto the combination of uncontrolled thyrotoxicosis, cardiac arrhythmias and anaesthesia has been regarded as potentially lethal. We have experienced situations when patients have been allowed to die of progressive cardiac failure because they were considered "too unfit" for anaesthesia. Although the patients in this series may represent a selection bias, we believe the outcomes support that anaesthesia for patients with AIT undergoing total thyroidectomy can be both safe and potentially life-saving.
